SCHEMBL14053013

SCHEMBL14053013

Cc1cccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.80
▸ PIK3CA P42336 1/20 0.80
▸ PIK3CB P42338 1/20 0.80
▸ PIK3CG P48736 1/20 0.80
▸ MEN1 O00255 7/20 0.66
▸ KMT2A Q03164 7/20 0.66
▸ ALDH1A1 P00352 4/20 0.66
▸ LMNA P02545 3/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ HPGD P15428 2/20 0.66
▸ MAPT P10636 11/20 0.52
▸ KDM4E B2RXH2 6/20 0.52
▸ GAA P10253 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ POLB P06746 2/20 0.50
▸ TTR P02766 1/20 0.50
▸ GFER P55789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1792641 0.89 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL22225686 0.87 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL22225700 0.85 PIK3CD (0.76) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL15095971 0.84 MEN1 (0.70) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL15096000 0.84 MEN1 (0.70) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL15095987 0.84 MEN1 (0.76) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL15095962 0.84 MEN1 (0.79) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL15256304 0.84 PIK3CD (0.66) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL1791900 0.84 MEN1 (0.72) PIK3CDPIK3CAPIK3CBPIK3CGMEN1
SCHEMBL6995384 0.83 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140100215-A1 Methods of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2014-04-10 — — US disclosed
US-8642584-B2 Method of using PI3K and MEK modulators EXELIXIS, INC. (US) 2014-02-04 — — US disclosed
US-8642584-B2 Method of using PI3K and MEK modulators EXELIXIS, INC. (US) 2014-02-04 — — US disclosed
US-20120302545-A1 Method of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100215-A1 Methods of Using PI3K and MEK Modulators PIK3CA, PIK3CD, PIK3R1 PIK3CD 2/4885PIK3CA 1/4885PIK3CB 9/4885
US-20120302545-A1 Method of Using PI3K and MEK Modulators PIK3CA, PIK3CD, PIK3R1 PIK3CD 2/4885PIK3CA 1/4885PIK3CB 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback